Perspective Therapeutics Appoints New CMO, Director
Ticker: CATX · Form: 8-K · Filed: Aug 30, 2024 · CIK: 728387
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
TL;DR
Perspective Therapeutics just hired a new CMO and added a director to the board.
AI Summary
Perspective Therapeutics, Inc. announced on August 26, 2024, the appointment of Dr. Jonathan M. Roth as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its Board of Directors. The company also disclosed compensatory arrangements for its officers. Perspective Therapeutics, Inc. was formerly known as Isoray, Inc. and IsoRay, Inc.
Why It Matters
The appointment of a new Chief Medical Officer and a new Board member can signal strategic shifts or new directions for the company's medical and governance strategies.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate internal shifts that may impact future performance.
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan M. Roth (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Jones (person) — Elected to Board of Directors
- Isoray, Inc. (company) — Former company name
- IsoRay, Inc. (company) — Former company name
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan M. Roth has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Jennifer L. Jones has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is August 26, 2024.
What was Perspective Therapeutics, Inc. formerly known as?
Perspective Therapeutics, Inc. was formerly known as Isoray, Inc. and IsoRay, Inc.
In which state was Perspective Therapeutics, Inc. incorporated?
Perspective Therapeutics, Inc. was incorporated in Delaware.
Filing Stats: 706 words · 3 min read · ~2 pages · Grade level 13.5 · Accepted 2024-08-30 16:10:09
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
- $138,360 — Austin will be entitled to receive (a) $138,360.75, an amount equal to approximately si
- $7,686 — e salary, and (b) a lump sum payment of $7,686.54, an amount equal to the employer por
Filing Documents
- catx-20240826.htm (8-K) — 38KB
- 0000950170-24-102338.txt ( ) — 146KB
- catx-20240826.xsd (EX-101.SCH) — 23KB
- catx-20240826_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: August 30, 2024 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer